Apotex Inc, a Canada-based global health company, announced on Thursday the commercial launch in Canada of Apo-Semaglutide Injection, a generic equivalent of Ozempic.

The product will be available across Canada within the coming weeks.

Apo-Semaglutide Injection is approved in 2 mg and 4 mg prefilled pen formats, providing 0.25 mg or 0.5 mg doses (2 mg pen; 0.68 mg/mL) and 1 mg doses (4 mg pen; 1.34 mg/mL).

Administered using a prefilled pen, with instructions for use consistent with brand-name semaglutide, Apo-Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus to improve glycaemic control, in combination with diet and exercise.

Apo-Semaglutide Injection was developed in partnership with Orbicular Pharmaceutical Technologies.